1、Issue 15,December 2024MARKET REPORTHIV2024The state of HIV treatment,testing,and prevention in low-and middle-income countries2 2024 CHAI HIV Market ReportDISCLAIMERThe data sources primarily used for analysis in the report include Clinton Health Access Initiative(CHAI)country teams,ministry of heal

2、th counterparts,stakeholder resources and conversations(e.g.Global Fund,PEPFAR,UNAIDS,Unitaid,WHO,and civil society partners),and published research.CHAI has taken precautions to verify the information shared in the report.However,the analysis in the report is not exhaustive,and the responsibility f

3、or the interpretation and use of the material lies with the reader.The mention of specific companies or products does not imply CHAIs endorsement or recommendation.ACKNOWLEDGMENTThis report was made possible through the generous support of Unitaid,with complementary support from the UK Foreign,Commo

4、nwealth&Development Office and the Bill&Melinda Gates Foundation.Front Cover:A clinician in Nigeria prepares a child for a blood draw to conduct viral load and CD4 testing.2024 CHAI HIV Market Report 3CONTENTSHIV Market ReportACRONYMS 4EXECUTIVE SUMMARY 6KEY HIV MARKET UPDATES 8PREVENTION 9TESTING 1

5、4ADVANCED HIV DISEASE 19ADULT TREATMENT 25PEDIATRIC TREATMENT 32TREATMENT MONITORING 37APPENDIX A:FORECASTED API DEMAND IN GA LMICS 40APPENDIX B:CHAI ARV BENCHMARK PRICE COMPARISON LIST 41APPENDIX C:NOTES ON METHODOLOGY 42APPENDIX D:REFERENCES 433HPThree months of weekly RPT+INH for TPTCrAgCryptococ

6、cal antigen3TCLamivudineCROIConference on Retroviruses and Opportunistic Infections5FCFlucytosine CVDCardiovascular diseaseABCAbacavirDcNPDrug-combination-nanoparticleAfrica CDCAfrica Centres for Disease Control and Prevention DPPDual prevention pillAHDAdvanced HIV diseaseDRV/rDarunavir/ritonavirAID